Advertisement
    In the last 8 hours
    Earlier today
    Yesterday
    Navigating Value, Efficacy in Modern CLL Treatment: Pierluigi Porcu, MD American Journal of Managed Care15:31 18-Apr-25
    Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL American Journal of Managed Care15:11 18-Apr-25
    AJMC® in the Press, April 18, 2025 American Journal of Managed Care14:10 18-Apr-25
    Where Will Eli Lilly Be in 5 Years? The Motley Fool09:54 18-Apr-25
    In the last 7 days
    Elinzanetant Effective for Menopause Symptoms Across BMI, Smoking Status American Journal of Managed Care22:14 17-Apr-25
    New Hope and Persistent Challenges for MASH Treatment: Naim Alkhouri, MD American Journal of Managed Care19:21 17-Apr-25
    Weight loss drug investigation The Portugal News18:07 16-Apr-25
    Trump Signs Executive Order to Lower Drug Prices American Journal of Managed Care16:45 16-Apr-25
    Personalized Care Key as Tirzepatide Use Expands Rapidly American Journal of Managed Care18:42 15-Apr-25
    Tirzepatide Surges, Overtakes Older Drugs in Diabetes, Obesity Care American Journal of Managed Care22:12 14-Apr-25
    Mounjaro Update: Week 45 The Nittany Turkey (Weblog)18:41 14-Apr-25
    New study finds weight loss drugs help burn fat, not muscle Knowridge Science Report01:49 13-Apr-25
    In the last month
    OrderlyMeds' Response to Eli Lilly's Cease-and-Desist Letter PR Newswire (Press Release)12:33 11-Apr-25
    Compounding Unlikely To Solve GLP-1 Affordable Access Issues Scrip Pharma Intelligence22:59 10-Apr-25
    Weight loss medicines in England The House of Commons Library blog16:50 10-Apr-25
    US Pharmaceutical Pipeline Expands With Innovation and Competition American Journal of Managed Care21:24 8-Apr-25
    view more headlines
    19 Apr 15:45

    About our Tirzepatide news

    Latest news on Tirzepatide, a drug that is being developed as a potential treatment for obesity and type 2 diabetes. It is a synthetic hormone that is designed to mimic the effects of natural hormones called incretins, which help to lower blood sugar and reduce appetite. Tirzepatide has shown promise in clinical trials, producing significant weight loss in people with obesity or type 2 diabetes. It is administered as a once-weekly injection, and it is believed to work by increasing the production of a hormone called GLP-1, which helps to regulate appetite and insulin production. Tirzepatide is currently in late-stage clinical trials, and it is expected to be considered for regulatory approval in the coming years.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.